Dr. Marie-Eve Boucher, McGill University Health Centre, Montréal, QC
Despite the fact that new diagnosis has been steadily increasing over the past years, malignant pleural mesothelioma remains a rare disease with a high fatality rate. Pleural mesothelioma is highly morbid and new treatment options are required to alleviate patient’s symptom and improve their life expectancy. Over the past 30 years, very few advances have been made in terms of local control. However, there are some development in systemic therapeutic options. This presentation will review current standard of care for pleural mesothelioma and recent data on possible new options of treatment.
At the end of this presentation, attendees will be able to:
- summarize the different systemic treatments of pleural mesothelioma;
- acquire information on potential novel therapies and ongoing trials; and
- improve their ability to manage palliative care.